SCHEMBL4970943

SCHEMBL4970943

Cc1cc(NCCCN2CC3CN(C(=O)c4c(C)ncnc4C)CC3C2)ccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 17/20 0.47
CCL5 P13501 11/20 0.46
KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3283596 0.93 CCL5 (0.49) CCR5CCL5KCNH2
Trifluoroacetic Acid SCHEMBL5534993 0.88 CCL5 (0.50) CCR5CCL5
SCHEMBL4694609 0.86 CCR5 (0.50) CCR5CCL5
SCHEMBL4693629 0.85 CCR5 (0.51) CCR5CCL5KCNH2
SCHEMBL14447202 0.85 CCL5 (0.47) CCR5CCL5KCNH2
SCHEMBL4972705 0.84 CCL5 (0.57) CCR5CCL5
SCHEMBL4695359 0.84 CCR5 (0.58) CCR5CCL5KCNH2
SCHEMBL3282227 0.83 CCR5 (0.51) CCR5CCL5KCNH2
SCHEMBL13359810 0.82 CCR5 (0.53) CCR5CCL5KCNH2
SCHEMBL4691539 0.81 ALDH1A1 (0.51) CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1987035-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2008-11-05 EP disclosed
WO-2007093515-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN LA-ROCHE AG (CH) 2007-08-23 WO disclosed
US-20070191406-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191406-A1 Heterocyclic antiviral compounds CCR5, CX3CR1, CXCR1 CCR5 1/4885CCL5 14/4885KCNH2 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.